Core Viewpoint - In December 2025, 15 funds managed by GF Fund experienced a decline of over 8%, with the GF Healthcare Mixed Fund A and C managed by Wu Xingwu leading the losses at -13.3% and -13.27% respectively [1][2]. Fund Performance Summary - The GF Healthcare Mixed Fund A and C have recorded a decline of 41.19% and 42.41% respectively since their inception on October 21, 2020 [1]. - The top ten holdings of the GF Healthcare Mixed Fund include companies such as Kelun-Botai Biotech, Innovent Biologics, and WuXi AppTec [1]. - Other funds managed by Wu Xingwu, including GF Hong Kong-Shenzhen Healthcare Mixed Fund A and C, also reported significant declines in December [2][3]. Additional Fund Details - The GF Healthcare Mixed Fund A had a unit net value of 0.5881 as of January 5, 2026, with a one-month decline of -6.59% and a one-year return of 38.28% [2]. - The GF Healthcare Mixed Fund C had a unit net value of 0.5759 as of January 5, 2026, with a one-month decline of -6.62% and a one-year return of 37.74% [2]. - Other funds with notable declines include the GF Medical Innovation Mixed Fund A and C, which fell by -12.79% and -12.75% respectively [3][4].

Core Viewpoint - The Hong Kong Innovative Drug ETF (159567) has shown a positive performance since its inception, with a slight increase in scale and significant trading activity in the early days of 2024 [1][2] Group 1: Fund Performance - The Hong Kong Innovative Drug ETF (159567) closed at a 0.38% increase on January 6, with a trading volume of 1.163 billion yuan [1] - As of January 5, the fund's latest share count was 10.479 billion shares, with a total scale of 8.331 billion yuan, reflecting a 5.50% increase in scale since December 31, 2025 [1] - The fund's management fee is set at 0.50% annually, and the custody fee is 0.10% annually [1] Group 2: Trading Activity - Over the past 20 trading days, the cumulative trading amount for the ETF reached 16.464 billion yuan, with an average daily trading amount of 0.823 billion yuan [1] - In the first two trading days of 2024, the ETF recorded a cumulative trading amount of 2.789 billion yuan, averaging 1.394 billion yuan per day [1] Group 3: Fund Holdings - The top holdings of the Hong Kong Innovative Drug ETF include companies such as BeiGene, CanSino Biologics, and Innovent Biologics, with significant percentages of the fund's total assets allocated to these stocks [2] - The largest holding is BeiGene, accounting for 10.62% of the portfolio, followed closely by CanSino Biologics at 10.55% and Innovent Biologics at 10.21% [2] - Other notable holdings include China National Pharmaceutical Group and Stone Group, with respective allocations of 9.62% and 7.56% [2]

Group 1 - The Hong Kong Innovative Drug ETF (159567) closed with a gain of 5.75% on January 5, with a trading volume of 1.625 billion yuan [1] - The fund was established on January 3, 2024, with an annual management fee of 0.50% and a custody fee of 0.10% [1] - As of December 31, 2025, the fund's shares stood at 10.492 billion, with a total size of 7.896 billion yuan, indicating no change in shares or size year-to-date [1] Group 2 - The ETF's recent trading activity shows a cumulative trading amount of 16.006 billion yuan over the last 20 trading days, with an average daily trading amount of 800 million yuan [1] - The current fund manager, Ma Jun, has managed the fund since its inception, achieving a return of 50.52% during the management period [1] - The ETF's top holdings include companies such as BeiGene, CanSino Biologics, and Innovent Biologics, with significant weightings in the portfolio [2]

Core Viewpoint - The Chinese asset market is experiencing a strong start in 2026, with significant gains in both A-shares and Hong Kong stocks, particularly in the healthcare and technology sectors, driven by favorable monetary policies and market sentiment [1][2][3]. A-Share Market Summary - A-shares have shown a robust performance, with the Shanghai Composite Index surpassing 4000 points and achieving a 12-day winning streak, the longest since 1993, with a trading volume exceeding 2.5 trillion yuan [1][2]. - The healthcare sector is leading the gains, with the Medical ETF (512170) rising by 5.29%, marking its largest single-day increase since October 2024, and a trading volume of 1.166 billion yuan, up over 211% from the previous day [3][5]. - The "AI Twins" in the technology sector are also performing well, with the Sci-Tech AI ETF (589520) increasing by 4.74%, and the Growth Board AI ETF (159363) rising over 3% to reach a new listing high [2][3]. Hong Kong Market Summary - The Hong Kong market has also seen a strong start, with the Hang Seng Index rising by 2.76% and the Hang Seng Technology Index increasing by 4% [1][2]. - The Hong Kong Stock Connect Innovation Drug ETF (520880) surged by 5.42%, achieving its largest single-day increase since its launch in July 2025, with a trading volume of 509 million yuan, up over 263% [5][6]. - The healthcare sector in Hong Kong is performing well, with significant gains in innovative drug stocks, and the Medical Theme Index rising by 3.66% [8]. Investment Outlook - Analysts from Galaxy Securities expect continued net inflows from foreign and southbound funds due to a favorable monetary policy environment, which could lead to substantial improvements in the profitability of Hong Kong-listed companies [2][8]. - CITIC Securities indicates a high probability of A-shares continuing their upward trend, supported by positive macroeconomic policies and a focus on technological innovation as a key driver for growth [2][8]. - The market is anticipated to benefit from a combination of rising profits and valuations, with a bullish outlook for 2026 [2][8].

Summary of Conference Call Records Industry Overview - The pharmaceutical sector showed strong performance in 2025, with the Guohai Pharmaceutical Index indicating a significant annual increase. However, 2026 is expected to present a more balanced market with multiple sub-sectors such as innovative drugs, CRO (Contract Research Organizations), traditional Chinese medicine, medical devices, and pharmacy distribution being favored [1][2][3]. Key Insights and Arguments - **Innovative Drugs**: The sector remains promising, with a strategic theme for 2026 titled "Innovative Drugs Going Global: From Initial Year to Major Year." The importance of Clinical Development Plans (CDP) is emphasized, recommending companies like Sanofi, Innovent Biologics, and KANGFANG Biopharma, while also highlighting KANGDE and Aidi Pharmaceutical [1][5]. - **CRO Sector**: The domestic CRO sector is viewed positively, benefiting from improved overseas demand and expectations of interest rate cuts by the Federal Reserve. Domestic demand is also expected to improve due to innovative drugs going global and better financing conditions [1][13]. - **Traditional Chinese Medicine**: The sales side is gradually recovering, with expectations for a strong start in Q1 2026. The sector is seen as having significant market share growth potential due to its consumer-oriented nature [1][16]. - **Retail Pharmacy**: The retail pharmacy sector is positioned for growth, with positive same-store sales data from leading chains. The sector is expected to benefit from the expansion of commercial health insurance and changes in basic medical insurance policies [1][14][15]. Notable Developments - **KANGDE**: The company has its dual formulation and three indications included in the medical insurance for the first time, expected to see significant volume in 2026. Aidi Pharmaceutical is also making strides in HIV treatment, with products expected to renew at original prices and maintain growth [1][7][12]. - **Claudin 18.2 ADC**: This product, owned by AstraZeneca, is set for global new drug application submission, indicating strong growth potential [1][9][10]. - **Surgical Robots**: The market for surgical robots is rapidly developing, with significant breakthroughs in overseas orders. Companies like Jingfeng Medical and MicroPort are performing well, with MicroPort ranking second globally in terms of order volume [1][17][18]. Challenges and Opportunities - **Domestic Drug Commercialization**: Domestic drugs face challenges in commercialization but are expected to enter hospitals after being included in medical insurance. The convenience of new formulations like KANGYUE's pre-filled syringe is highlighted [1][8]. - **Commercial Health Insurance**: The commercial health insurance sector is showing significant growth potential, with new policies expected to expand coverage for innovative products [1][19]. - **Basic Medical Insurance Changes**: Recent changes in basic medical insurance policies, including inter-provincial pooling and long-term care insurance, are anticipated to release medical demand and alleviate financial pressures [1][20][21]. Conclusion - The pharmaceutical industry is poised for a diverse and balanced growth trajectory in 2026, with various sub-sectors showing promise. Key players in innovative drugs, CRO, and retail pharmacy are expected to benefit from favorable market conditions and policy changes, while challenges in commercialization and competition remain.

Market Overview - A-shares showed strong performance with major indices achieving gains at the start of 2026, with the Shanghai Composite Index returning to 4000 points [1] - The Hong Kong stock market also experienced slight gains despite geopolitical tensions arising from the U.S. military action in Venezuela [1] Geopolitical Impact - The U.S. military operation in Venezuela, resulting in the capture of President Maduro, is seen as a strategic move by President Trump to assert U.S. influence in South America and potentially seize Venezuelan oil resources [1][2] - This event is expected to have negative repercussions for stability in South America and could impact Chinese investments in Venezuela, which amount to over $60 billion [2] Insurance Industry - The insurance sector experienced a strong start to the year, with leading companies reporting new policy premium growth rates between 40% and 60% [3] - The influx of funds into insurance is attributed to the maturity of significant deposits, with insurance rates being more attractive than some bank deposits [3] Brain-Computer Interface Market - Neuralink, led by Elon Musk, plans to begin large-scale production of brain-computer interface devices by 2026, with the global market projected to reach approximately $12.4 billion by 2034 [3] - Companies in the brain-computer interface sector saw significant stock price increases, with some rising nearly 40% [3] Pharmaceutical Industry - The 44th J.P. Morgan Healthcare Conference is set to attract over 8,000 participants, highlighting the growing interest in the pharmaceutical sector [4] - In 2025, China approved 76 innovative drugs, significantly surpassing the previous year's total, and the total value of drug licensing transactions exceeded $130 billion [4] Robotics Sector - U Tree Technology clarified reports regarding its IPO status, while home robotics company Woan Robotics announced plans to launch a humanoid household robot in January 2026 [5] - Woan Robotics has shown a compound annual growth rate of 49% in revenue over the past three years, leading to a stock price increase of over 19% [5] Semiconductor Industry - The National Integrated Circuit Fund increased its stake in SMIC from 4.79% to 9.25%, indicating strong support for domestic semiconductor development [6] - Companies in the semiconductor sector, including SMIC and Huahong Semiconductor, experienced stock price increases [6] Nuclear Energy Sector - Tokyo Electric Power Company plans to restart the Kashiwazaki-Kariwa Nuclear Power Plant, which may impact uranium supply dynamics [7] - Companies involved in uranium mining, such as CGN Mining, saw stock price increases due to expectations of tighter supply [7] Real Estate Market - A recent article emphasized the importance of stabilizing the real estate market, with new tax policies aimed at reducing transaction costs for home sales [8] - The reduction of capital gains tax on property sales is expected to stimulate demand for new homes and facilitate market liquidity [8] Construction Machinery Industry - Zoomlion reported strong domestic and international sales growth, with a projected increase in sales of construction machinery [9] - The company is expanding its presence in the global market and has plans for significant investments in research and development [10][11]

Industry Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Outperform the Market" and is maintained [1] Core Insights - The retail pharmacy industry is undergoing accelerated consolidation, with a significant reduction in the number of stores, leading to increased concentration benefiting leading players [4][15] - The number of retail pharmacies in China has decreased by nearly 20,000 since the fourth quarter of 2024, with a net reduction of 8,800 stores in the third quarter of 2025 alone [15][21] - Leading pharmacies are expected to see profit margins improve in 2026 due to operational optimizations and cost control measures [5][21] - The innovation drug sector is currently in a correction phase, but the maturation of clinical data is expected to drive future market performance [7][25] - The medical device sector is showing signs of recovery, with leading companies reporting improved performance in the third quarter of 2025 [29][30] Summary by Sections Industry Overview - The closing index for the pharmaceutical and biotechnology sector is 8084.61, with a 52-week high of 9323.49 and a low of 6764.34 [1] Recent Market Performance - The A-share pharmaceutical and biotechnology sector fell by 2.06% in the last week of December 2025, underperforming the CSI 300 index by 1.47 percentage points [6][22] - The retail pharmacy sector experienced a decline of 4.11% during the same period [22] Retail Pharmacy Insights - The retail pharmacy industry is seeing a rapid exit of smaller players, with a focus on consolidating market share among leading pharmacies [15][37] - The implementation of drug traceability codes is expected to further increase industry concentration by raising operational costs for smaller pharmacies [20] Innovation Drug Sector - The innovation drug sector is experiencing a correction, but the maturation of clinical data is anticipated to be a key driver for future performance [7][25] - Companies with stable business development (BD) expectations are recommended for investment, including Innovent Biologics and 3SBio [26] Medical Device Sector - The medical device industry is expected to benefit from improved procurement processes and a reduction in the pressure from centralized procurement [29][30] - Leading companies are showing signs of recovery, with Q3 performance improving compared to earlier in the year [29] Traditional Chinese Medicine - The traditional Chinese medicine sector is under pressure but is expected to benefit from policies favoring essential medicines and inventory clearance [34][36]

Group 1 - The A-share medical sector experienced a significant rally on January 5, 2026, led by the brain-computer interface concept, with key stocks like Sanbo Brain Science, Meihao Medical, and Lepu Medical hitting the 20% daily limit up [1] - The largest medical ETF in the market, tracking the medical index, surged by 5.29% to reach its highest point since October 9, 2024, with a trading volume of 1.166 billion yuan, an increase of over 211% compared to the previous trading day [1] - In the Hong Kong market, the medical sector also performed strongly, particularly in innovative drugs, with the Hong Kong Innovation Drug ETF rising by 5.42%, marking its largest single-day increase since its launch in July 2025 [2] Group 2 - Elon Musk announced on social media that his brain-computer interface company, Neuralink, will begin mass production of brain-computer interface devices in 2026, indicating a significant advancement in the technology [3] - According to CITIC Securities, China's research in brain-computer interface technology is relatively advanced globally, which is expected to enhance the valuations of related listed companies and stimulate financing in the primary market [3] - The National Medical Products Administration reported that 76 innovative drugs were approved for market in 2025, setting a historical record, with total licensing transactions exceeding $130 billion [5] Group 3 - The Hong Kong medical sector saw a collective rise in various concepts, including brain-computer interfaces and internet healthcare, with stocks like Microneuro Science and Brain Dynamics-B increasing by 19.73% and 15.74%, respectively [5] - The upcoming listing of the Hong Kong medical ETF Huabao (159137) is anticipated to attract attention, as it tracks the medical theme index [5] - Long-term strategies in the medical sector remain focused on innovation, with expectations for strong performance in 2026, particularly in innovative medical devices and drugs [5]

Group 1 - The global stock market has seen a significant rise, with the Hang Seng Index increasing nearly 3% in the first week of the new year, particularly driven by the innovative drug sector, which is expected to continue its rebound [1][2] - The innovative drug sector was previously affected by liquidity issues and year-end accounting effects, but the current market conditions present an opportunity for investors as the sector has returned to levels seen in June 2025 [1][2] - The recent comments from Trump regarding Venezuelan oil extraction, which could increase oil supply by approximately 30%, are expected to exert downward pressure on inflation and raise the likelihood of interest rate cuts by the Federal Reserve, benefiting the innovative drug sector [1][2] Group 2 - The innovative drug sector is anticipated to remain a key investment theme in 2025, with the Hang Seng Innovative Drug Index having outperformed the Hang Seng Technology Index significantly, showing a 64% increase compared to the latter's 23% [4] - The sector has experienced a remarkable rebound, with a peak increase of over 116%, although it has since retraced to levels seen in June 2025 due to overall market weakness [4][20] - The trend of overseas licensing deals for Chinese innovative drug companies has become a norm, with several high-value transactions occurring, such as a $60 billion deal between 3SBio and Pfizer, indicating strong international interest [6][8][11] Group 3 - The innovative drug sector is benefiting from supportive policies that have shifted focus towards quality, reducing previous concerns about profitability in the domestic market [14][19] - The introduction of measures to stabilize pricing and ensure quality in the procurement process is expected to positively impact innovative drug companies [16][19] - The overall valuation of the innovative drug sector has adjusted downwards, making it more attractive for investment, especially with the anticipated increase in business development (BD) transactions and favorable monetary policy [20][22] Group 4 - The innovative drug sector's performance is expected to be bolstered by a series of upcoming medical conferences, which are typically high points for BD transactions, providing opportunities for early investment [13] - The sector's growth is supported by a multi-faceted payment system that includes insurance and government funding, creating a conducive environment for rapid expansion [19] - Investment in innovative drugs can be effectively achieved through ETFs, such as the E Fund Innovative Drug ETF (159316), which focuses on leading companies in the sector [22][24]

公司名稱: 三生制药（「本公司」） 呈交日期: 2026年1月5日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01530 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | | 增加 / 減少 (-) | | | | | | | USD | | | | 本月底結存 | | | 50,000,000,000 | USD | | 0.00001 | USD | | 500,000 | 本月底法定/註冊股本總額： USD 500,000 FF301 第 1 頁 共 10 頁 v 1.1.1 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券 ...